Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 7/20 | 0.57 |
| ▸ | CTSL | P07711 | 9/20 | 0.54 |
| ▸ | CTSS | P25774 | 4/20 | 0.54 |
| ▸ | CTSK | P43235 | 4/20 | 0.54 |
| ▸ | F3 | P13726 | 7/20 | 0.52 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6181749 | 0.89 | CTSB (0.57) | CTSBCTSLCTSSCTSKF3 | |
| SCHEMBL6182874 | 0.88 | CTSB (0.61) | CTSBCTSLCTSSCTSKF3 | |
| SCHEMBL6181881 | 0.87 | F3 (0.54) | CTSBCTSLCTSSCTSKF3 | |
| SCHEMBL6203497 | 0.87 | CTSB (0.55) | CTSBCTSLCTSSCTSKF3 | |
| SCHEMBL7449976 | 0.86 | CTSB (0.57) | CTSBCTSLCTSSCTSKF3 | |
| SCHEMBL6182148 | 0.84 | CTSB (0.55) | CTSBCTSLCTSSCTSKF3 | |
| SCHEMBL6182433 | 0.83 | CTSB (0.53) | CTSBCTSLCTSSCTSKF3 | |
| SCHEMBL7450448 | 0.81 | CTSB (0.58) | CTSBCTSLCTSSCTSKF3 | |
| SCHEMBL6182791 | 0.81 | CTSB (0.61) | CTSBCTSLCTSSCTSKCTSF | |
| SCHEMBL6183809 | 0.81 | CTSB (0.61) | CTSBCTSLCTSSCTSKCTSF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1161415-B1 | N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS | AXYS PHARM INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-6593327-B2 | N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates | AXYS PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| US-20030119788-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-06-26 | — | — | US | disclosed |
| US-6476026-B1 | Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020086996-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086996-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | CTSB 11/4885CTSL 14/4885CTSS 10/4885 |
| US-20030119788-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | CTSB 11/4885CTSL 14/4885CTSS 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.